| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/24/2003 | US20030139331 Treatment of cancer by reduction of intracellular energy and pyrimidines |
| 07/24/2003 | US20030139330 Transcription factors containing two potential dna binding motifs |
| 07/24/2003 | US20030139328 Complexing; modulating biological activation |
| 07/24/2003 | US20030139327 Nucleic acids, proteins, and antibodies |
| 07/24/2003 | US20030139325 Complex comprising OCIF and polysaccharide |
| 07/24/2003 | US20030139323 Preradiation therapy; side effect reduction |
| 07/24/2003 | US20030138879 Phosphopantetheinyl transferases and uses thereof |
| 07/24/2003 | US20030138864 Comparing expression levels of genes or proteins in human tissue or cells from normal and tumor origin, selecting enzyme of which mRNA or protein levels in tumor tissue are higher by two-fold as compared to normal cells or tissue |
| 07/24/2003 | US20030138833 Psoriasin expression by breast epithelial cells |
| 07/24/2003 | US20030138793 Kit for identifying the origin of tumors in prostate, breast, colorectal, lung, ovarian, gastroesophageal, pancreatic, liver, kidney or bladder cells by way of probes for analyzing marker gene expression |
| 07/24/2003 | US20030138559 Process for manufacturing a metered dose inhaler |
| 07/24/2003 | US20030138548 Weight management system for obese animals |
| 07/24/2003 | US20030138547 Pet food includes 35-70% by weight protein, 4-10% by weight fat, 5-25% by weight fiber, 10-35% by weight digestible carbohydrate, 0.1-1% by weight functional ingredient to build lean muscle mass |
| 07/24/2003 | US20030138543 Food product supplemented with proteoglycan precursors |
| 07/24/2003 | US20030138511 Antiallergic agents, drugs, foods, drinks or cosmetics containing them and process for producing the same |
| 07/24/2003 | US20030138510 Stabilizing proanthocyanidin with an amino acid having a hydroxyl group or its dipeptide |
| 07/24/2003 | US20030138508 Method for administering an analgesic |
| 07/24/2003 | US20030138505 Intradermal-penetration agents for topical local anesthetic administration |
| 07/24/2003 | US20030138504 Cold compounded that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant |
| 07/24/2003 | US20030138503 Topical pharmaceutical formulations and methods of treatment |
| 07/24/2003 | US20030138502 Method for protecting human skin |
| 07/24/2003 | US20030138500 Pesticidal composition |
| 07/24/2003 | US20030138499 Stable surgical irrigating solutions |
| 07/24/2003 | US20030138494 Topical applying a therapeutic prostaglandins to cause vasodilation, active material dispersed in a gel polymer blends containing an anionic polymer and a nonionic polymer |
| 07/24/2003 | US20030138493 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
| 07/24/2003 | US20030138489 An aqueous solution comprising of propofol, poloxamers; noncontamination, stability |
| 07/24/2003 | US20030138484 Chewable tablet containing lysine |
| 07/24/2003 | US20030138483 The filler contains an alcohol to dissolve the drug and maintain in solution; treating human immunodeficiency virus infections |
| 07/24/2003 | US20030138481 Liposomes |
| 07/24/2003 | US20030138477 Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
| 07/24/2003 | US20030138476 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall |
| 07/24/2003 | US20030138467 Methods for improving the aesthetic appearance of skin |
| 07/24/2003 | US20030138466 Topical products with antioxidant formulations to prevent UV-induced carcinogenesis and photoaging and to modulate desquamatory skin disorders; comprising 40 wt-% urea, 0.1-20 wt-% antioxidant, balance excipients |
| 07/24/2003 | US20030138464 Method and apparatus for improved heat controlled administration of pharmaceuticals |
| 07/24/2003 | US20030138462 Prepared by slurrying pamidronic acid in water, combining with aqueous sodium hydroxide in a 2:1 molar ratio, sealing in unit dosage forms |
| 07/24/2003 | US20030138458 HCV E1E2 vaccine compositions |
| 07/24/2003 | US20030138430 Drug combinations containing an agent that arrests target cells in the G2 (cell enlargement) and/or M phase (DNA replication) of the cell cycle and another drug that targets an internalising cell surface structure e.g. an antigen |
| 07/24/2003 | US20030138423 Antiinflammation agents and immunotherapy using an enzyme inhibitor; sepsis; antiarthritic and - ulcer agents; colitis; myocarditis; glomerulonephritis; gastrointestinal and nervous system disorders; Crohn's disease; automimmune |
| 07/24/2003 | US20030138416 Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| 07/24/2003 | US20030138414 Modulators of methylation for control of bacterial virulence |
| 07/24/2003 | US20030138413 Activating dendritic cells from the host which are rendered hyporesponsive to activation stimuli by the disease by administering a tumor-derived DC inhibitory factor antagonist in combination with a Toll-like receptor agonist |
| 07/24/2003 | US20030138407 Therapeutic methods for nucleic acid delivery vehicles |
| 07/24/2003 | US20030138403 Interferon formulations |
| 07/24/2003 | US20030138399 Anti-inflammatory therapy for inflammatory mediated infection |
| 07/24/2003 | US20030138397 Anionic polymers as toxin binders and antibacterial agents |
| 07/24/2003 | US20030138396 Administering a lipase inhibitor and a pharmaceutically acceptable bile acid sequestrant; anticholesterol agents |
| 07/24/2003 | US20030138394 Slimming agents with anticellulite action; saponins |
| 07/24/2003 | US20030138390 Aging resistance |
| 07/24/2003 | US20030138385 Method of preventing mucositis |
| 07/24/2003 | US20030138382 Delivery of caffeine through an inhalation route |
| 07/24/2003 | US20030138379 Methods for treating urinary incontinence in mammals |
| 07/24/2003 | US20030136698 Medicinal product package for eradication therapy |
| 07/24/2003 | CA2706833A1 Geranyl compounds |
| 07/24/2003 | CA2706826A1 Geranyl compounds |
| 07/24/2003 | CA2700690A1 Process for producing reformatsky reagent in stable form |
| 07/24/2003 | CA2651604A1 Method for preparation of substantially amorphous telmisartan |
| 07/24/2003 | CA2474239A1 Substituted pyridazinones as inhibitors of p38 |
| 07/24/2003 | CA2474154A1 Methods for treating eye disorders |
| 07/24/2003 | CA2474141A1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof |
| 07/24/2003 | CA2474127A1 4-oxo-4, 7-dihydrofuro¬2,3-b|pyridine-5-carboxamide antiviral agents |
| 07/24/2003 | CA2474014A1 Pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid |
| 07/24/2003 | CA2473908A1 Compounds for blocking androgen receptors |
| 07/24/2003 | CA2473893A1 Stable salts of o-acetylsalicylic acid with basic amino acids ii |
| 07/24/2003 | CA2473570A1 Antisense compounds directed against human csf-1 |
| 07/24/2003 | CA2473441A1 Beta-secretase inhibitors |
| 07/24/2003 | CA2473374A1 Phenyl sulfoxides and phenyl sulfones |
| 07/24/2003 | CA2473236A1 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues |
| 07/24/2003 | CA2473207A1 Halogenobenzylaminopropionic acid derivatives |
| 07/24/2003 | CA2473170A1 Therapeutic acridone and acridine compounds |
| 07/24/2003 | CA2473039A1 Novel anti-igf-ir antibodies and uses thereof |
| 07/24/2003 | CA2472993A1 Oxothieno (3, 2-b) pyridinecarboxamides as antiviral agents |
| 07/24/2003 | CA2472746A1 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| 07/24/2003 | CA2472619A1 Fused pyrimidine derivates as rho-kinase inhibitors |
| 07/24/2003 | CA2472470A1 Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
| 07/24/2003 | CA2472468A1 Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
| 07/24/2003 | CA2472459A1 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections |
| 07/24/2003 | CA2472419A1 Coumarin derivatives, process for their production and use thereof |
| 07/24/2003 | CA2472395A1 Pantoprazole cyclodextrin inclusion complexes |
| 07/24/2003 | CA2472377A1 Crystalline solids of carvedilol and processes for their preparation |
| 07/24/2003 | CA2472223A1 Derivatives of alpha-phenylthiocarboxylic and alpha-phenyloxy-carboxylic acids useful for the treatment of diseases responding to pparalpha activation |
| 07/24/2003 | CA2472209A1 Pheny(alkyl)carboxylic acid derivatives and dionic phenylalkylheterocyclic derivatives and their use as medicines with serum glucose and/or serum lipid lowering activity |
| 07/24/2003 | CA2472204A1 N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/24/2003 | CA2472199A1 Treatment involving peroxisome proliferator-activated receptor-gamma agonist and cyclooxygenase-2 selective inhibitors |
| 07/24/2003 | CA2472170A1 Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression |
| 07/24/2003 | CA2472168A1 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/24/2003 | CA2472160A1 Quinazolinone compounds in combined modalities for improved cancer treatment |
| 07/24/2003 | CA2471899A1 Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
| 07/24/2003 | CA2471817A1 Labeling targeting agents with gallium-68 and gallium-67 |
| 07/24/2003 | CA2471620A1 Pyrrolidone carboxamides |
| 07/24/2003 | CA2471562A1 Tyrosyl derivatives and their use as p2x7 receptor modulators |
| 07/24/2003 | CA2471513A1 Macrophage migration inhibitory factor (mif) promoter polymorphism in inflammatory disease |
| 07/24/2003 | CA2471480A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 07/24/2003 | CA2471314A1 Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives |
| 07/24/2003 | CA2471311A1 Aromatic thioether liver x-receptor modulators |
| 07/24/2003 | CA2471309A1 Synthesis of combretastatin a-2 prodrugs |
| 07/24/2003 | CA2470649A1 Mmp inhibitors |
| 07/24/2003 | CA2470430A1 Compositions comprising collagen and metalloprotease inhibitors |
| 07/24/2003 | CA2470413A1 Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |
| 07/24/2003 | CA2470359A1 Assay for the detection of factors that modulate the expression of ingap |
| 07/24/2003 | CA2470293A1 Use of an anti-microtubule agent for the treatment of uveitis |